Development asset linked to Vaccinex in public FDA and regional records.
pharma · Colon Carcinoma Metastatic in the Liver · Metastatic Melanoma · VCNX
Vaccinex
VACCINEX, INC.
Vaccinex drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1895 Mt Hope Ave, Rochester, New York 14620, US HQ
28 Employees
Public company Type
VCNX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1895 Mt Hope Ave, Rochester, New York 14620, US
- Employees
- 28
- Programs
- 11
- Drugs
- 8
- Patents
- 41
Vaccinex pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Vaccinex drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Vaccinex in public FDA and regional records.
-
avelumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 other
-
Development asset linked to Vaccinex in public FDA and regional records.
-
ipilimumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
Development asset linked to Vaccinex in public FDA and regional records.
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Vaccinex in public FDA and regional records.